The Phase 1/2 data strongly de-risk NGN-401 and support a potential best-in-class profile. The stock is likely to re-rate upward on this catalyst. Key next catalyst is Embolden topline data in 2H 2027; monitor for analyst upgrades and increased institutional interest in the near term.
Price Chart
Executive Summary
Neurogene reported highly positive long-term Phase 1/2 data for NGN-401 gene therapy in Rett syndrome: 100% of 10 participants gained developmental milestones (avg 4.7), 80% met the Embolden registrational trial's composite responder definition at 12 months, and gains deepened through 30 months with no plateau or safety concerns. The data significantly de-risk the program and support a clear path to BLA, with the fully enrolled Embolden trial (N=25) expected to report topline results in 2H 2027.
Key Facts
- 100% of Phase 1/2 participants (N=10) gained ≥1 developmental milestone and improved on CGI-I at 12 months
- 47 total milestones gained, average 4.7 per participant; milestone gains increased 95% from 6 to 12 months and 147% from 6 to 12 months
- 80% (8/10) met the Embolden composite responder definition (CGI-I ≥3 + ≥1 milestone) at 12 months, exceeding the pre-specified 33% success threshold by 2.4x
- Median time to first clinical improvement was 2 months; no plateau or milestone loss through 30 months of follow-up
- RSGMS: 5.2-point increase vs 0.8-point decrease in natural history (p<0.001); RSHFS: 100% improved hand function vs 15% in natural history (p<0.001)
- NGN-401 at 1E15 vg dose generally well-tolerated; no treatment-related SAEs or DLTs in the Embolden trial (N=35 total safety database)
- Embolden registrational trial fully dosed (N=25, overenrolled by 25%); topline data expected 2H 2027
Financial Impact
No financial data in filing. Positive clinical data supports potential approval for a large unmet need (15,000-20,000 patients US/EU/UK) with no approved disease-modifying therapies, implying significant commercial opportunity if approved.
Risk Factors
- Embolden registrational trial may fail to replicate Phase 1/2 results in a larger, more diverse population
- Safety signals could emerge with longer follow-up or in the broader Embolden cohort
- Competitive gene therapy programs for Rett syndrome could emerge
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001404644-26-000046 |
| Document: ngne-20260629.htm | 0001404644-26-000046 |
| Document: ngne_irsf2026datapressrele.htm | 0001404644-26-000046 |
| Document: 0001404644-26-000046-index-headers.html | 0001404644-26-000046 |
| Document: 0001404644-26-000046-index.html | 0001404644-26-000046 |
| Document: 0001404644-26-000046.txt | 0001404644-26-000046 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G | $25.87 | awaiting T+20 | — | $23.60 (−8.77%) |
Oct 6, 2026 20d ago | SC 13G | $25.45 | awaiting T+20 | — | $23.60 (−7.27%) |
Aug 11, 2026 11w ago | 8-K | $36.55 $37.88 | ▲ +3.64% | ▲ +4.70% | $23.60 (−35.43%) |
Jun 30, 2026 16w ago | 424B5 | $33.88 $33.66 | ▲ +0.65% | ▼ −1.54% | $23.60 (+30.34%) |
Jun 29, 2026 17w ago | 8-K | $32.28 $34.90 | ▲ +8.12% | ▲ +8.40% | $23.60 (−26.89%) |
Jun 8, 2026 20w ago | 8-K | $28.60 $32.56 | ▲ +13.85% | ▲ +12.21% | $23.60 (−17.48%) |
Apr 20, 2026 27w ago | 8-K | $27.74 $27.98 | ▲ +0.87% | ▼ −3.34% | $23.60 (−14.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers